Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury

被引:37
作者
Hwang, YYC
Shaw, S
Kaneko, M
Redd, H
Marrero, MB
Ramasamy, R
机构
[1] Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA
[2] Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA
关键词
protein kinase C; niacin; sorbitol dehydrogenase;
D O I
10.1096/fj.04-2780fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The aldose reductase pathway has been demonstrated to be a key component of myocardial ischemia reperfusion injury. Previously, we demonstrated that increased lactate/pyruvate ratio, a measure of cytosolic NADH/NAD+, is an important change that drives the metabolic cascade mediating ischemic injury. This study investigated signaling mechanisms by which the aldose reductase pathway mediates myocardial ischemic injury. Specifically, the influence of the aldose reductase pathway flux on JAK-STAT signaling was examined in perfused hearts. Induction of global ischemia in rats resulted in JAK2 activation followed by STAT5 activation. Pharmacological inhibition of aldose reductase or sorbitol dehydrogenase blocked JAK2 and STAT5 activation and was associated with lower lactate/pyruvate ratio and lower protein kinase C activity. Niacin, known to lower cytosolic NADH/NAD+ ratio independent of the aldose reductase pathway inhibition, also blocked JAK2 and STAT5 activation. Inhibition of protein kinase C also blocked JAK2 and STAT5 activation. Transgenic mice overexpressing human aldose reductase exhibited increased JAK2 and STAT5 activation. Pharmacological inhibition of JAK2 reduced ischemic injury and improved functional recovery similar to that observed in aldose reductase pathway inhibited mice hearts. These data, for the first time, demonstrate JAK-STAT signaling by the aldose reductase pathway in ischemic hearts and is, in part, due to changes in cytosolic redox state.
引用
收藏
页码:795 / +
页数:19
相关论文
共 27 条
[1]
Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: Role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure [J].
Booz, GW ;
Day, JNE ;
Baker, KM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2002, 34 (11) :1443-1453
[2]
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor [J].
Changelian, PS ;
Flanagan, ME ;
Ball, DJ ;
Kent, CR ;
Magnuson, KS ;
Martin, WH ;
Rizzuti, BJ ;
Sawyer, PS ;
Perry, BD ;
Brissette, WH ;
McCurdy, SP ;
Kudlacz, EM ;
Conklyn, MJ ;
Elliott, EA ;
Koslov, ER ;
Fisher, MB ;
Strelevitz, TJ ;
Yoon, K ;
Whipple, DA ;
Sun, JM ;
Munchhof, MJ ;
Doty, JL ;
Casavant, JM ;
Blumenkopf, TA ;
Hines, M ;
Brown, MF ;
Lillie, BM ;
Subramanyam, C ;
Shang-Poa, C ;
Milici, AJ ;
Beckius, GE ;
Moyer, JD ;
Su, CY ;
Woodworth, TG ;
Gaweco, AS ;
Beals, CR ;
Littman, BH ;
Fisher, DA ;
Smith, JF ;
Zagouras, P ;
Magna, HA ;
Saltarelli, MJ ;
Johnson, KS ;
Nelms, LF ;
Des Etages, SG ;
Hayes, LS ;
Kawabata, TT ;
Finco-Kent, D ;
Baker, DL ;
Larson, M .
SCIENCE, 2003, 302 (5646) :875-878
[3]
Ischemic protection and myofibrillar cardiomyopathy -: Dose-dependent effects of in vivo δPKC inhibition [J].
Hahn, HS ;
Yussman, MG ;
Toyokawa, T ;
Marreez, Y ;
Barrett, TJ ;
Hilty, KC ;
Osinska, H ;
Robbins, J ;
Dorn, GW .
CIRCULATION RESEARCH, 2002, 91 (08) :741-748
[4]
Role of STAT3 in ischemic preconditioning [J].
Hattori, R ;
Maulik, N ;
Otani, H ;
Zhu, L ;
Cordis, G ;
Engelman, RM ;
Siddiqui, MAQ ;
Das, DK .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2001, 33 (11) :1929-1936
[5]
Aldose reductase activation is a key component of myocardial response to ischemia [J].
Hwang, YC ;
Sato, SN ;
Tsai, JY ;
Yan, SD ;
Bakr, S ;
Zhang, HP ;
Oates, PJ ;
Ramasamy, R .
FASEB JOURNAL, 2001, 15 (14) :243-+
[6]
Central role for aldose reductase pathway in myocardial ischemic injury [J].
Hwang, YYC ;
Kaneko, M ;
Bakr, S ;
Liao, H ;
Lu, Y ;
Lewis, ER ;
Yan, SD ;
Ii, S ;
Itakura, M ;
Rui, L ;
Skopicki, H ;
Homma, S ;
Schmidt, AM ;
Oates, PJ ;
Szabolcs, M ;
Ramasamy, R .
FASEB JOURNAL, 2004, 18 (11) :1192-1199
[7]
Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium [J].
Hwang, YYC ;
Bakr, S ;
Ellery, CA ;
Oates, PJ ;
Ramasamy, R .
FASEB JOURNAL, 2003, 17 (13) :2331-+
[8]
Additive protection of the ischemic heart ex vivo by combined treatment with δ-protein kinase C inhibitor and ε-protein kinase C activator [J].
Inagaki, K ;
Hahn, HS ;
Dorn, GW ;
Mochly-Rosen, D .
CIRCULATION, 2003, 108 (07) :869-875
[9]
PREFERENTIAL ELEVATION OF PROTEIN-KINASE-C ISOFORM-BETA-II AND DIACYLGLYCEROL LEVELS IN THE AORTA AND HEART OF DIABETIC RATS - DIFFERENTIAL REVERSIBILITY TO GLYCEMIC CONTROL BY ISLET CELL TRANSPLANTATION [J].
INOGUCHI, T ;
BATTAN, R ;
HANDLER, E ;
SPORTSMAN, JR ;
HEATH, W ;
KING, GL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (22) :11059-11063
[10]
Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor [J].
Ishii, H ;
Jirousek, MR ;
Koya, D ;
Takagi, C ;
Xia, P ;
Clermont, A ;
Bursell, SE ;
Kern, TS ;
Ballas, LM ;
Heath, WF ;
Stramm, LE ;
Feener, EP ;
King, GL .
SCIENCE, 1996, 272 (5262) :728-731